Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Thomas Van den Broeck; Roderick C.N. van den Bergh; Erik Briers; Philip Cornford; Marcus Cumberbatch; Derya Tilki; Maria De Santis; Stefano Fanti; Nicola Fossati; Silke Gillessen; Jeremy P. Grummet; Ann M. Henry; Michael Lardas; Matthew Liew; Malcolm Mason; Lisa Moris; Ivo G. Schoots; Theodorus van der Kwast; Henk van der Poel; Thomas Wiegel; Peter Paul M. Willemse; Olivier Rouvière; Thomas B. Lam; Nicolas Mottet

doi:10.1016/j.euf.2019.06.004

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Thomas Van den Broeck^*, Roderick C.N. van den Bergh, Erik Briers, Philip Cornford, Marcus Cumberbatch, Derya Tilki, Maria De Santis, Stefano Fanti, Nicola Fossati, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Michael Lardas, Matthew Liew, Malcolm Mason, Lisa Moris, Ivo G. Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas WiegelPeter Paul M. Willemse, Olivier Rouvière, Thomas B. Lam, Nicolas Mottet

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

123 Citations (Scopus)

Abstract

Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

Original language	English
Pages (from-to)	231-234
Number of pages	4
Journal	European Urology Focus
Volume	6
Issue number	2
Early online date	24 Jun 2019
DOIs	https://doi.org/10.1016/j.euf.2019.06.004
Publication status	Published - 15 Mar 2020

Bibliographical note

Funding Information:
Financial disclosures: Thomas Van den Broeck certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Henk van Der Poel is a company consultant for Intuitive Surgical, has participated in trials for Astellas and Steba Biotech, and has received grant and research support from Astellas. Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; receives company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participates in trials from Ferring; and receives fellowships and travel grants from Astellas and Janssen. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Ann M. Henry is a company consultant for Nucletron-Elektra; participates in trials by Cancer Research UK and the National Institute of Health Research (UK); has received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and has received research grants from Cancer Research UK and the Sir John Fisher Foundation. Malcolm Mason is a company consultant for Ellipses Pharma and Oncotherics. Thomas Wiegel is a member of the advisory board for IPSEN, receives company speaker honoraria from IPSEN and Hexal, is a member of the Janssen Steering Committee, and has participated in the ATLAS/AUO trial. Silke Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; has received speaker honoraria from Janssen and Novartis; and participates in multiple trials for different companies. Olivier Rouvière has received company speaker honoraria from EDAP-TMS, participates in trials by ESAO-TMS and Vermon, and has received research and travel grants from Philips. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, and SOTIO; participates in various trials as a member of the EORTC GU group; and has received research grants from Pierre Fabre Oncologie and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Derya Tilki is a company consultant for Steba Biotech and MDx Health; has received speaker honoraria from Mundipharma, Astellas, and Ribose-pharm; participates in trials by MDxHealth; has received travel and research grants from Janssen; and is a member of the PIONEER consortium. Stefano Fanti is a company consultant for Bayer and ANMI; has received speaker honoraria from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen, and Roche. Thomas Van den Broeck, Roderick C.N. van den Bergh, Lisa Moris, Erik Briers, Marcus Cumberbatch, Nicola Fossati, Jeremy P. Grummet, Michael Lardas, Matthew Liew, Ivo G. Schoots, Peter-Paul M. Willemse, and Theodorus Van Der Kwast have nothing to disclose.

Publisher Copyright:
© 2019 European Association of Urology

Keywords

Biochemical recurrence
European Association of Urology
Gleason score
Guidelines
Prognostic factors
Prostate cancer
PSA kinetics
Radical prostatectomy
Radiotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euf.2019.06.004Licence: Unspecified

Cite this

Van den Broeck, T., van den Bergh, R. C. N., Briers, E., Cornford, P., Cumberbatch, M., Tilki, D., De Santis, M., Fanti, S., Fossati, N., Gillessen, S., Grummet, J. P., Henry, A. M., Lardas, M., Liew, M., Mason, M., Moris, L., Schoots, I. G., van der Kwast, T., van der Poel, H., ... Mottet, N. (2020). Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus, 6(2), 231-234. https://doi.org/10.1016/j.euf.2019.06.004

Van den Broeck, T, van den Bergh, RCN, Briers, E, Cornford, P, Cumberbatch, M, Tilki, D, De Santis, M, Fanti, S, Fossati, N, Gillessen, S, Grummet, JP, Henry, AM, Lardas, M, Liew, M, Mason, M, Moris, L, Schoots, IG, van der Kwast, T, van der Poel, H, Wiegel, T, Willemse, PPM, Rouvière, O, Lam, TB & Mottet, N 2020, 'Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations', European Urology Focus, vol. 6, no. 2, pp. 231-234. https://doi.org/10.1016/j.euf.2019.06.004

@article{963c80b5b723468fb8b40934692ccc98,

title = "Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations",

abstract = "Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.",

keywords = "Biochemical recurrence, European Association of Urology, Gleason score, Guidelines, Prognostic factors, Prostate cancer, PSA kinetics, Radical prostatectomy, Radiotherapy",

author = "{Van den Broeck}, Thomas and {van den Bergh}, {Roderick C.N.} and Erik Briers and Philip Cornford and Marcus Cumberbatch and Derya Tilki and {De Santis}, Maria and Stefano Fanti and Nicola Fossati and Silke Gillessen and Grummet, {Jeremy P.} and Henry, {Ann M.} and Michael Lardas and Matthew Liew and Malcolm Mason and Lisa Moris and Schoots, {Ivo G.} and {van der Kwast}, Theodorus and {van der Poel}, Henk and Thomas Wiegel and Willemse, {Peter Paul M.} and Olivier Rouvi{\`e}re and Lam, {Thomas B.} and Nicolas Mottet",

note = "Funding Information: Financial disclosures: Thomas Van den Broeck certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Henk van Der Poel is a company consultant for Intuitive Surgical, has participated in trials for Astellas and Steba Biotech, and has received grant and research support from Astellas. Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; receives company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participates in trials from Ferring; and receives fellowships and travel grants from Astellas and Janssen. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Ann M. Henry is a company consultant for Nucletron-Elektra; participates in trials by Cancer Research UK and the National Institute of Health Research (UK); has received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and has received research grants from Cancer Research UK and the Sir John Fisher Foundation. Malcolm Mason is a company consultant for Ellipses Pharma and Oncotherics. Thomas Wiegel is a member of the advisory board for IPSEN, receives company speaker honoraria from IPSEN and Hexal, is a member of the Janssen Steering Committee, and has participated in the ATLAS/AUO trial. Silke Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; has received speaker honoraria from Janssen and Novartis; and participates in multiple trials for different companies. Olivier Rouvi{\`e}re has received company speaker honoraria from EDAP-TMS, participates in trials by ESAO-TMS and Vermon, and has received research and travel grants from Philips. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, and SOTIO; participates in various trials as a member of the EORTC GU group; and has received research grants from Pierre Fabre Oncologie and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Derya Tilki is a company consultant for Steba Biotech and MDx Health; has received speaker honoraria from Mundipharma, Astellas, and Ribose-pharm; participates in trials by MDxHealth; has received travel and research grants from Janssen; and is a member of the PIONEER consortium. Stefano Fanti is a company consultant for Bayer and ANMI; has received speaker honoraria from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen, and Roche. Thomas Van den Broeck, Roderick C.N. van den Bergh, Lisa Moris, Erik Briers, Marcus Cumberbatch, Nicola Fossati, Jeremy P. Grummet, Michael Lardas, Matthew Liew, Ivo G. Schoots, Peter-Paul M. Willemse, and Theodorus Van Der Kwast have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2020",

month = mar,

day = "15",

doi = "10.1016/j.euf.2019.06.004",

language = "English",

volume = "6",

pages = "231--234",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Biochemical Recurrence in Prostate Cancer

T2 - The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

AU - Van den Broeck, Thomas

AU - van den Bergh, Roderick C.N.

AU - Briers, Erik

AU - Cornford, Philip

AU - Cumberbatch, Marcus

AU - Tilki, Derya

AU - De Santis, Maria

AU - Fanti, Stefano

AU - Fossati, Nicola

AU - Gillessen, Silke

AU - Grummet, Jeremy P.

AU - Henry, Ann M.

AU - Lardas, Michael

AU - Liew, Matthew

AU - Mason, Malcolm

AU - Moris, Lisa

AU - Schoots, Ivo G.

AU - van der Kwast, Theodorus

AU - van der Poel, Henk

AU - Wiegel, Thomas

AU - Willemse, Peter Paul M.

AU - Rouvière, Olivier

AU - Lam, Thomas B.

AU - Mottet, Nicolas

N1 - Funding Information: Financial disclosures: Thomas Van den Broeck certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Henk van Der Poel is a company consultant for Intuitive Surgical, has participated in trials for Astellas and Steba Biotech, and has received grant and research support from Astellas. Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; receives company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; participates in trials from Ferring; and receives fellowships and travel grants from Astellas and Janssen. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and Ipsen. Ann M. Henry is a company consultant for Nucletron-Elektra; participates in trials by Cancer Research UK and the National Institute of Health Research (UK); has received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and has received research grants from Cancer Research UK and the Sir John Fisher Foundation. Malcolm Mason is a company consultant for Ellipses Pharma and Oncotherics. Thomas Wiegel is a member of the advisory board for IPSEN, receives company speaker honoraria from IPSEN and Hexal, is a member of the Janssen Steering Committee, and has participated in the ATLAS/AUO trial. Silke Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; has received speaker honoraria from Janssen and Novartis; and participates in multiple trials for different companies. Olivier Rouvière has received company speaker honoraria from EDAP-TMS, participates in trials by ESAO-TMS and Vermon, and has received research and travel grants from Philips. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, and SOTIO; participates in various trials as a member of the EORTC GU group; and has received research grants from Pierre Fabre Oncologie and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Derya Tilki is a company consultant for Steba Biotech and MDx Health; has received speaker honoraria from Mundipharma, Astellas, and Ribose-pharm; participates in trials by MDxHealth; has received travel and research grants from Janssen; and is a member of the PIONEER consortium. Stefano Fanti is a company consultant for Bayer and ANMI; has received speaker honoraria from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen, and Roche. Thomas Van den Broeck, Roderick C.N. van den Bergh, Lisa Moris, Erik Briers, Marcus Cumberbatch, Nicola Fossati, Jeremy P. Grummet, Michael Lardas, Matthew Liew, Ivo G. Schoots, Peter-Paul M. Willemse, and Theodorus Van Der Kwast have nothing to disclose. Publisher Copyright: © 2019 European Association of Urology

PY - 2020/3/15

Y1 - 2020/3/15

N2 - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

AB - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

KW - Biochemical recurrence

KW - European Association of Urology

KW - Gleason score

KW - Guidelines

KW - Prognostic factors

KW - Prostate cancer

KW - PSA kinetics

KW - Radical prostatectomy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85067674484&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.06.004

DO - 10.1016/j.euf.2019.06.004

M3 - Article

C2 - 31248850

AN - SCOPUS:85067674484

SN - 2405-4569

VL - 6

SP - 231

EP - 234

JO - European Urology Focus

JF - European Urology Focus

IS - 2

ER -

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this